Polgreen, L. E. Et Al. 2023. Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study. HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 2 , 28-29.

Polgreen, L. E., Savarirayan, R., Tofts, L., Irving, M., Wilcox, W., Bacino, C. A., ... Hoover-Fong, J.(2023). Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study. HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 2, 28-29.

Polgreen, Lynda Et Al. "Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study," HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 2, 28-29, 2023

Polgreen, Lynda E. Et Al. "Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study." HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 2, pp.28-29, 2023

Polgreen, L. E. Et Al. (2023) . "Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study." HORMONE RESEARCH IN PAEDIATRICS , no.SUPPL 2, pp.28-29.

@article{article, author={Lynda E. Polgreen Et Al. }, title={Persistent and stable growth promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: results from an ongoing Phase 3 extension study}, journal={HORMONE RESEARCH IN PAEDIATRICS}, year=2023, pages={28-29} }